New biologics could help defeat infant respiratory infections

30 July 2020

Results published in the New England Journal of Medicine (NEJM) indicate that a new kind of immunization could help protect premature babies from respiratory syncytial viruses (RSV).

AstraZeneca (LSE: AZN) and Sanofi (Euronext: SAN) have published Phase IIb data for nirsevimab, an extended half-life monoclonal antibody under development as a passive immunisation for lower respiratory tract infections (LTRI) caused by RSVs.

Meeting the primary endpoint of the trial, nirsevimab achieved a statistically-significant 70.1% reduction in medically-attended RSV LRTI compared to placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK